Skip to main content

Advertisement

SpringerLink
Log in

Cardiotoxicity Induced by Antifungal Drugs

  • Pharmacology and Pharmacodynamics of Antifungal Agents (P Gubbins, Section Editor)
  • Published:
Current Fungal Infection Reports Aims and scope Submit manuscript

Abstract

This review addresses the potential of antifungal drugs to cause cardiac toxicity. Many antifungal drugs, especially antifungal azoles, rarely cause torsades de pointes (TdP) and carry the risk of sudden death. Interventions to avoid TdP should include cautious use of azoles in combination with other drugs that cause QTc prolongation, and elimination of risk factors for TdP whenever possible. These risk factors include: hypokalemia, hypomagnesemia, severe bradycardia, and preexisting long QT syndrome. ECG monitoring should be considered when the use of multiple QT-prolonging drugs is unavoidable and TdP risk factors cannot be resolved. Itraconazole exhibits negative inotropic activity which may present as worsening heart failure in patients with preexisting heart failure. A few cases of severe bradycardia have also been described with voriconazole. Most cases of cardiac toxicity associated with amphotericin B are due to severe electrolyte abnormalities, rapid administration or overdose. Although cardiac toxicity is not common with the use of antifungal drugs, recognition of the potential to cause serious cardiac-related outcomes, evaluation of risk factors, and monitoring is warranted.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Yap YG, Camm AJ. Drug induced QT prolongation and torsades de pointes. Heart. 2003;89(11):1363–72.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  2. Bhatia A, Sra J, Akhtar M. Repolarization syndromes. Curr Probl Cardiol. 2012;37(8):317–62. doi:10.1016/j.cpcardiol.2012.03.004.

    Article  PubMed  Google Scholar 

  3. Vandenberg JI, Perry MD, Perrin MJ, Mann SA, Ke Y, Hill AP. hERG K(+) channels: structure, function, and clinical significance. Physiol Rev. 2012;92(3):1393–478. Presents a comprehensive review of the hERG channel function from a physological standpoint. The article is recommended for readers who want to have a more in-depth understanding of the pathophysiology of QT prolongation.

    Article  CAS  PubMed  Google Scholar 

  4. Ahmad SR, Singer SJ, Leissa BG. Congestive heart failure associated with itraconazole. Lancet. 2001;357(9270):1766–7. doi:10.1016/S0140-6736(00)04891-1.

    Article  CAS  PubMed  Google Scholar 

  5. Goldenberg I, Moss AJ. Long QT syndrome. J Am Coll Cardiol. 2008;51(24):2291–300. doi:10.1016/j.jacc.2008.02.068.

    Article  PubMed  Google Scholar 

  6. Schwartz PJ, Crotti L, Insolia R. Long-QT syndrome: from genetics to management. Circ Arrhythm Electrophysiol. 2012;5(4):868–77. doi:10.1161/CIRCEP.111.962019.

    Article  PubMed Central  PubMed  Google Scholar 

  7. Crotti L, Celano G, Dagradi F, Schwartz PJ. Congenital long QT syndrome. Orphanet J Rare Dis. 2008;3:18. doi:10.1186/1750-1172-3-18.

    Article  PubMed Central  PubMed  Google Scholar 

  8. Hedley PL, Jorgensen P, Schlamowitz S, Wangari R, Moolman-Smook J, Brink PA, et al. The genetic basis of long QT and short QT syndromes: a mutation update. Hum Mutat. 2009;30(11):1486–511. doi:10.1002/humu.21106.

    Article  CAS  PubMed  Google Scholar 

  9. Witchel HJ. Drug-induced hERG block and long QT syndrome. Cardiovasc Ther. 2011;29(4):251–9. doi:10.1111/j.1755-5922.2010.00154.x.

    Article  CAS  PubMed  Google Scholar 

  10. Antzelevitch C. Drug-induced spatial dispersion of repolarization. Cardiol J. 2008;15(2):100–21.

    PubMed Central  PubMed  Google Scholar 

  11. Vos MA, Verduyn SC, Gorgels AP, Lipcsei GC, Wellens HJ. Reproducible induction of early afterdepolarizations and torsade de pointes arrhythmias by d-sotalol and pacing in dogs with chronic atrioventricular block. Circulation. 1995;91(3):864–72.

    Article  CAS  PubMed  Google Scholar 

  12. Abi-Gerges N, Valentin JP, Pollard CE. Dog left ventricular midmyocardial myocytes for assessment of drug-induced delayed repolarization: short-term variability and proarrhythmic potential. Br J Pharmacol. 2010;159(1):77–92. doi:10.1111/j.1476-5381.2009.00338.x.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  13. Varro A, Balati B, Iost N, Takacs J, Virag L, Lathrop DA, et al. The role of the delayed rectifier component IKs in dog ventricular muscle and Purkinje fibre repolarization. J Physiol. 2000;523(Pt 1):67–81.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  14. Fenichel RR, Malik M, Antzelevitch C, Sanguinetti M, Roden DM, Priori SG, et al. Drug-induced torsades de pointes and implications for drug development. J Cardiovasc Electrophysiol. 2004;15(4):475–95.

    Article  PubMed Central  PubMed  Google Scholar 

  15. Behr ER, Roden D. Drug-induced arrhythmia: pharmacogenomic prescribing? Eur Heart J. 2013;34(2):89–95.

    Article  PubMed Central  PubMed  Google Scholar 

  16. John RM, Tedrow UB, Koplan BA, Albert CM, Epstein LM, Sweeney MO, et al. Ventricular arrhythmias and sudden cardiac death. Lancet. 2012;380(9852):1520–9. doi:10.1016/S0140-6736(12)61413-5.

    Article  PubMed  Google Scholar 

  17. Ray WA, Murray KT, Meredith S, Narasimhulu SS, Hall K, Stein CM. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med. 2004;351(11):1089–96. doi:10.1056/NEJMoa040582.

    Article  CAS  PubMed  Google Scholar 

  18. Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM. Azithromycin and the risk of cardiovascular death. N Engl J Med. 2012;366(20):1881–90.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  19. Han S, Zhang Y, Chen Q, Duan Y, Zheng T, Hu X, et al. Fluconazole inhibits hERG K(+) channel by direct block and disruption of protein trafficking. Eur J Pharmacol. 2011;650(1):138–44. doi:10.1016/j.ejphar.2010.10.010.

    Article  CAS  PubMed  Google Scholar 

  20. Berl T, Wilner KD, Gardner M, Hansen RA, Farmer B, Baris BA, et al. Pharmacokinetics of fluconazole in renal failure. J Am Soc Nephrol. 1995;6(2):242–7.

    CAS  PubMed  Google Scholar 

  21. Poluzzi E, Raschi E, Moretti U, De Ponti F. Drug-induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS). Pharmacoepidemiol Drug Saf. 2009;18(6):512–8.

    Article  CAS  PubMed  Google Scholar 

  22. Manosuthi W, Sungkanuparph S, Anekthananon T, Supparatpinyo K, Nolen TL, Zimmer LO, et al. Effect of high-dose fluconazole on QT interval in patients with human immunodeficiency virus (HIV)-associated cryptococcal meningitis. Int J Antimicrob Agents. 2009;34(5):494–6. doi:10.1016/j.ijantimicag.2009.05.009.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  23. McMahon JH, Grayson ML. Torsades de pointes in a patient receiving fluconazole for cerebral cryptococcosis. Am J Health Syst Pharm. 2008;65(7):619–23. doi:10.2146/ajhp070203.

    Article  CAS  PubMed  Google Scholar 

  24. Khazan M, Mathis AS. Probable case of torsades de pointes induced by fluconazole. Pharmacotherapy. 2002;22(12):1632–7.

    Article  PubMed  Google Scholar 

  25. Dorsey ST, Biblo LA. Prolonged QT interval and torsades de pointes caused by the combination of fluconazole and amitriptyline. Am J Emerg Med. 2000;18(2):227–9.

    Article  CAS  PubMed  Google Scholar 

  26. Esch JJ, Kantoch MJ. Torsades de Pointes ventricular tachycardia in a pediatric patient treated with fluconazole. Pediatr Cardiol. 2008;29(1):210–3. doi:10.1007/s00246-007-9076-0.

    Article  PubMed  Google Scholar 

  27. Gandhi PJ, Menezes PA, Vu HT, Rivera AL, Ramaswamy K. Fluconazole- and levofloxacin-induced torsades de pointes in an intensive care unit patient. Am J Health Syst Pharm. 2003;60(23):2479–83.

    PubMed  Google Scholar 

  28. Wassmann S, Nickenig G, Bohm M. Long QT syndrome and torsade de pointes in a patient receiving fluconazole. Ann Intern Med. 1999;131(10):797.

    Article  CAS  PubMed  Google Scholar 

  29. Tholakanahalli VN, Potti A, Hanley JF, Merliss AD. Fluconazole-induced torsade de pointes. Ann Pharmacother. 2001;35(4):432–4.

    Article  CAS  PubMed  Google Scholar 

  30. Tacken MC, Bracke FA, Van Zundert AA. Torsade de pointes during sevoflurane anesthesia and fluconazole infusion in a patient with long QT syndrome. A case report. Acta Anaesthesiol Belg. 2011;62(2):105–8.

    CAS  PubMed  Google Scholar 

  31. Chakravarty C, Singh PM, Trikha A, Arora MK. Fluconazole-induced recurrent ventricular fibrillation leading to multiple cardiac arrests. Anaesth Intensive Care. 2009;37(3):477–80.

    CAS  PubMed  Google Scholar 

  32. Pham CP, de Feiter PW, van der Kuy PH, van Mook WN. Long QTc interval and torsade de pointes caused by fluconazole. Ann Pharmacother. 2006;40(7–8):1456–61. doi:10.1345/aph.1G741.

    Article  PubMed  Google Scholar 

  33. Tatetsu H, Asou N, Nakamura M, Hanaoka N, Matsuno F, Horikawa K, et al. Torsades de pointes upon fluconazole administration in a patient with acute myeloblastic leukemia. Am J Hematol. 2006;81(5):366–9. doi:10.1002/ajh.20557.

    Article  CAS  PubMed  Google Scholar 

  34. Hinterseer M, Irlbeck M, Ney L, Beckmann BM, Pfeufer A, Steinbeck G, et al. Acute respiratory distress syndrome with transiently impaired left ventricular function and Torsades de Pointes arrhythmia unmasking congenital long QT syndrome in a 25-yr-old woman. Br J Anaesth. 2006;97(2):150–3. doi:10.1093/bja/ael118.

    Article  CAS  PubMed  Google Scholar 

  35. Mok NS, Lo YK, Tsui PT, Lam CW. Ketoconazole induced torsades de pointes without concomitant use of QT interval-prolonging drug. J Cardiovasc Electrophysiol. 2005;16(12):1375–7.

    PubMed  Google Scholar 

  36. Alkan Y, Haefeli WE, Burhenne J, Stein J, Yaniv I, Shalit I. Voriconazole-induced QT interval prolongation and ventricular tachycardia: a non-concentration-dependent adverse effect. Clin Infect Dis. 2004;39(6):e49–52. doi:10.1086/423275.

    Article  CAS  PubMed  Google Scholar 

  37. Aypar E, Kendirli T, Tutar E, Ciftci E, Ince E, Ileri T, et al. Voriconazole-induced QT interval prolongation and torsades de pointes. Pediatr Int. 2011;53(5):761–3. doi:10.1111/j.1442-200X.2010.03321.x.

    Article  CAS  PubMed  Google Scholar 

  38. Philips JA, Marty FM, Stone RM, Koplan BA, Katz JT, Baden LR. Torsades de pointes associated with voriconazole use. Transpl Infect Dis. 2007;9(1):33–6. doi:10.1111/j.1399-3062.2006.00160.x.

    Article  CAS  PubMed  Google Scholar 

  39. Elbey MA, Cil H, Onturk E, Islamoglu Y. QTc prolongation and torsade de pointes ventricular tachycardia in a small dose voriconazole therapy. Eur Rev Med Pharmacol Sci. 2012;16(1):100–2.

    CAS  PubMed  Google Scholar 

  40. Reinhold JA, Sanoski CA, Russo AM, Cooper JM, Spinler SA. Torsades de pointes associated with methadone and voriconazole. BMJ Case Rep. 2009;2009. doi:10.1136/bcr.07.2009.2119.

  41. Eiden C, Peyriere H, Tichit R, Cociglio M, Amedro P, Blayac JP, et al. Inherited long QT syndrome revealed by antifungals drug-drug interaction. J Clin Pharm Ther. 2007;32(3):321–4. doi:10.1111/j.1365-2710.2007.00812.x.

    Article  CAS  PubMed  Google Scholar 

  42. Hreiche R, Morissette P, Turgeon J. Drug-induced long QT syndrome in women: review of current evidence and remaining gaps. Gend Med. 2008;5(2):124–35. doi:10.1016/j.genm.2008.05.005.

    Article  PubMed  Google Scholar 

  43. Takemasa H, Nagatomo T, Abe H, Kawakami K, Igarashi T, Tsurugi T, et al. Coexistence of hERG current block and disruption of protein trafficking in ketoconazole-induced long QT syndrome. Br J Pharmacol. 2008;153(3):439–47.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  44. Daneshmend TK, Warnock DW, Ene MD, Johnson EM, Potten MR, Richardson MD, et al. Influence of food on the pharmacokinetics of ketoconazole. Antimicrob Agents Chemother. 1984;25(1):1–3.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  45. Rajput SK, Singh JN, Sharma SS. Evaluation of terfenadine and ketoconazole-induced QT prolongation in conscious telemetered guinea pigs. Pharmacol Rep. 2010;62(4):683–8.

    Article  CAS  PubMed  Google Scholar 

  46. Chaikin P, Gillen MS, Malik M, Pentikis H, Rhodes GR, Roberts DJ. Co-administration of ketoconazole with H1-antagonists ebastine and loratadine in healthy subjects: pharmacokinetic and pharmacodynamic effects. Br J Clin Pharmacol. 2005;59(3):346–54. doi:10.1111/j.1365-2125.2005.02348.x.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  47. Tyl B, Kabbaj M, Azzam S, Sologuren A, Valiente R, Reinbolt E, et al. Lack of significant effect of bilastine administered at therapeutic and supratherapeutic doses and concomitantly with ketoconazole on ventricular repolarization: results of a thorough QT study (TQTS) with QT-concentration analysis. J Clin Pharmacol. 2012;52(6):893–903.

    Article  CAS  PubMed  Google Scholar 

  48. Justo D, Zeltser D. Torsade de pointes induced by systemic antifungal agents: lessons from a retrospective analysis of published case reports. Mycoses. 2006;49(6):463–70. doi:10.1111/j.1439-0507.2006.01278.x.

    Article  PubMed  Google Scholar 

  49. NoorZurani MH, Vicknasingam B, Narayanan S. Itraconazole-induced torsade de pointes in a patient receiving methadone substitution therapy. Drug Alcohol Rev. 2009;28(6):688–90.

    Article  PubMed  Google Scholar 

  50. Cruccu V, Pedretti D, Confalonieri F. A case of pulmonary aspergillosis effectively treated with itraconazole. Possible interaction of the antimycotic agent with hydroquinidine. Clin Ter. 1995;146(5):383–9.

    CAS  PubMed  Google Scholar 

  51. Kaukonen KM, Olkkola KT, Neuvonen PJ. Itraconazole increases plasma concentrations of quinidine. Clin Pharmacol Ther. 1997;62(5):510–7.

    Article  CAS  PubMed  Google Scholar 

  52. Tsimogianni AM, Andrianakis I, Betrosian A, Douzinas E. Cardiac arrest provoked by itraconazole and amiodarone interaction: a case report. J Med Case Rep. 2011;5:333. doi:10.1186/1752-1947-5-333.

    Article  PubMed Central  PubMed  Google Scholar 

  53. Pohjola-Sintonen S, Viitasalo M, Toivonen L, Neuvonen P. Itraconazole prevents terfenadine metabolism and increases risk of torsades de pointes ventricular tachycardia. Eur J Clin Pharmacol. 1993;45(2):191–3.

    Article  CAS  PubMed  Google Scholar 

  54. Park JY, Shon JH, Kim KA, Jung HJ, Shim JC, Yoon YR, et al. Combined effects of itraconazole and CYP2D6*10 genetic polymorphism on the pharmacokinetics and pharmacodynamics of haloperidol in healthy subjects. J Clin Psychopharmacol. 2006;26(2):135–42. doi:10.1097/01.jcp.0000203199.88581.c3.

    Article  CAS  PubMed  Google Scholar 

  55. Okuyan H, Altin C. Heart failure induced by itraconazole. Indian J Pharmacol. 2013;45(5):524–5. doi:10.4103/0253-7613.117751.

    Article  PubMed Central  PubMed  Google Scholar 

  56. Qu Y, Fang M, Gao B, Amouzadeh HR, Li N, Narayanan P, et al. Itraconazole decreases left ventricular contractility in isolated rabbit heart: mechanism of action. Toxicol Appl Pharmacol. 2013;268(2):113–22. doi:10.1016/j.taap.2013.01.029.

    Article  CAS  PubMed  Google Scholar 

  57. Fung SL, Chau CH, Yew WW. Cardiovascular adverse effects during itraconazole therapy. Eur Respir J. 2008;32(1):240. doi:10.1183/09031936.00021208.

    Article  PubMed  Google Scholar 

  58. Gelfand MS, Cleveland KO. Acute congestive heart failure and death secondary to itraconazole therapy. AIDS. 2012;26(14):1848–50. doi:10.1097/QAD.0b013e3283574eb4.

    Article  PubMed  Google Scholar 

  59. Perbet S, Blondonnet R, Guerin R, Cayot-Constantin S, Constantin JM. Voriconazole-induced bradycardia without QT interval prolongation: a possible non-concentration-dependent adverse effect. Intensive Care Med. 2013;39(3):531–2. doi:10.1007/s00134-012-2776-9.

    Article  PubMed  Google Scholar 

  60. Jeong S, Nguyen PD, Desta Z. Comprehensive in vitro analysis of voriconazole inhibition of eight cytochrome P450 (CYP) enzymes: major effect on CYPs 2B6, 2C9, 2C19, and 3A. Antimicrob Agents Chemother. 2009;53(2):541–51.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  61. Moton A, Krishna G, Wang Z. Tolerability and safety profile of posaconazole: evaluation of 18 controlled studies in healthy volunteers. J Clin Pharm Ther. 2009;34(3):301–11. doi:10.1111/j.1365-2710.2009.01055.x.

    Article  CAS  PubMed  Google Scholar 

  62. Raad II, Graybill JR, Bustamante AB, Cornely OA, Gaona-Flores V, Afif C, et al. Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin Infect Dis. 2006;42(12):1726–34. doi:10.1086/504328.

    Article  CAS  PubMed  Google Scholar 

  63. Nelson S, Leung J. QTc prolongation in the intensive care unit: a review of offending agents. AACN Adv Crit Care. 2011;22(4):289–95. doi:10.1097/NCI.0b013e31822db49d. quiz 296–7.

    Article  PubMed  Google Scholar 

  64. Owens Jr RC, Nolin TD. Antimicrobial-associated QT interval prolongation: pointes of interest. Clin Infect Dis. 2006;43(12):1603–11. doi:10.1086/508873.

    Article  CAS  PubMed  Google Scholar 

  65. Poluzzi E, Raschi E, Motola D, Moretti U, De Ponti F. Antimicrobials and the risk of torsades de pointes: the contribution from data mining of the US FDA Adverse Event Reporting System. Drug Saf. 2010;33(4):303–14.

    Article  CAS  PubMed  Google Scholar 

  66. Damkier P, Hansen LL, Brosen K. Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine. Br J Clin Pharmacol. 1999;48(6):829–38.

    CAS  PubMed Central  PubMed  Google Scholar 

  67. Lessard E, Fortin A, Belanger PM, Beaune P, Hamelin BA, Turgeon J. Role of CYP2D6 in the N-hydroxylation of procainamide. Pharmacogenetics. 1997;7(5):381–90.

    Article  CAS  PubMed  Google Scholar 

  68. Zhang L, Fitzloff JF, Engel LC, Cook CS. Species difference in stereoselective involvement of CYP3A in the mono-N-dealkylation of disopyramide. Xenobiotica. 2001;31(2):73–83.

    Article  CAS  PubMed  Google Scholar 

  69. Hanyok JJ. Clinical pharmacokinetics of sotalol. Am J Cardiol. 1993;72(4):19A–26A.

    Article  CAS  PubMed  Google Scholar 

  70. Yamreudeewong W, DeBisschop M, Martin LG, Lower DL. Potentially significant drug interactions of class III antiarrhythmic drugs. Drug Saf. 2003;26(6):421–38.

    Article  CAS  PubMed  Google Scholar 

  71. Carrillo JA, Ramos SI, Herraiz AG, Llerena A, Agundez JA, Berecz R, et al. Pharmacokinetic interaction of fluvoxamine and thioridazine in schizophrenic patients. J Clin Psychopharmacol. 1999;19(6):494–9.

    Article  CAS  PubMed  Google Scholar 

  72. Miceli JJ, Smith M, Robarge L, Morse T, Laurent A. The effects of ketoconazole on ziprasidone pharmacokinetics – a placebo-controlled crossover study in healthy volunteers. Br J Clin Pharmacol. 2000;49 Suppl 1:71S–6S.

    CAS  PubMed Central  PubMed  Google Scholar 

  73. Grimm SW, Richtand NM, Winter HR, Stams KR, Reele SB. Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics. Br J Clin Pharmacol. 2006;61(1):58–69.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  74. Mahatthanatrakul W, Sriwiriyajan S, Ridtitid W, Boonleang J, Wongnawa M, Rujimamahasan N, et al. Effect of cytochrome P450 3A4 inhibitor ketoconazole on risperidone pharmacokinetics in healthy volunteers. J Clin Pharm Ther. 2012;37(2):221–5.

    Article  CAS  PubMed  Google Scholar 

  75. Jung SM, Kim KA, Cho HK, Jung IG, Park PW, Byun WT, et al. Cytochrome P450 3A inhibitor itraconazole affects plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients. Clin Pharmacol Ther. 2005;78(5):520–8.

    Article  CAS  PubMed  Google Scholar 

  76. Liu P, Foster G, Labadie R, Somoza E, Sharma A. Pharmacokinetic interaction between voriconazole and methadone at steady state in patients on methadone therapy. Antimicrob Agents Chemother. 2007;51(1):110–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  77. Cobb MN, Desai J, Brown Jr LS, Zannikos PN, Rainey PM. The effect of fluconazole on the clinical pharmacokinetics of methadone. Clin Pharmacol Ther. 1998;63(6):655–62.

    Article  CAS  PubMed  Google Scholar 

  78. Shi HY, Yan J, Zhu WH, Yang GP, Tan ZR, Wu WH, et al. Effects of erythromycin on voriconazole pharmacokinetics and association with CYP2C19 polymorphism. Eur J Clin Pharmacol. 2010;66(11):1131–6.

    Article  PubMed Central  PubMed  Google Scholar 

  79. Afrin LB, Afrin JB. Value of preemptive CYP2C19 genotyping in allogeneic stem cell transplant patients considered for pentamidine administration. Clin Transplant. 2011;25(3):E271–5.

    Article  CAS  PubMed  Google Scholar 

  80. Stass H, Nagelschmitz J, Moeller JG, Delesen H. Pharmacokinetics of moxifloxacin are not influenced by a 7-day pretreatment with 200 mg oral itraconazole given once a day in healthy subjects. Int J Clin Pharmacol Ther. 2004;42(1):23–9.

    Article  CAS  PubMed  Google Scholar 

  81. Kim KA, Park JY, Lee JS, Lim S. Cytochrome P450 2C8 and CYP3A4/5 are involved in chloroquine metabolism in human liver microsomes. Arch Pharm Res. 2003;26(8):631–7.

    Article  CAS  PubMed  Google Scholar 

  82. Projean D, Baune B, Farinotti R, Flinois JP, Beaune P, Taburet AM, et al. In vitro metabolism of chloroquine: identification of CYP2C8, CYP3A4, and CYP2D6 as the main isoforms catalyzing N-desethylchloroquine formation. Drug Metab Dispos. 2003;31(6):748–54.

    Article  CAS  PubMed  Google Scholar 

  83. Ridtitid W, Wongnawa M, Mahatthanatrakul W, Raungsri N, Sunbhanich M. Ketoconazole increases plasma concentrations of antimalarial mefloquine in healthy human volunteers. J Clin Pharm Ther. 2005;30(3):285–90.

    Article  CAS  PubMed  Google Scholar 

  84. Wisedpanichkij R, Chaijaroenkul W, Sangsuwan P, Tantisawat J, Boonprasert K, Na-Bangchang K. In vitro antimalarial interactions between mefloquine and cytochrome P450 inhibitors. Acta Trop. 2009;112(1):12–5.

    Article  CAS  PubMed  Google Scholar 

  85. Zeuli JD, Wilson JW, Estes LL. Effect of combined fluoroquinolone and azole use on QT prolongation in hematology patients. Antimicrob Agents Chemother. 2013;57(3):1121–7. doi:10.1128/AAC.00958-12.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  86. Bowler WA, Weiss PJ, Hill HE, Hoffmeister KA, Fleck RP, Blacky AR, et al. Risk of ventricular dysrhythmias during 1-hour infusions of amphotericin B in patients with preserved renal function. Antimicrob Agents Chemother. 1992;36(11):2542–3.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  87. Barcia JP. Hyperkalemia associated with rapid infusion of conventional and lipid complex formulations of amphotericin B. Pharmacotherapy. 1998;18(4):874–6.

    CAS  PubMed  Google Scholar 

  88. Groot OA, Trof RJ, Girbes AR, Swart NL, Beishuizen A. Acute refractory hyperkalaemia and fatal cardiac arrest related to administration of liposomal amphotericin B. Neth J Med. 2008;66(10):433–7.

    CAS  PubMed  Google Scholar 

  89. Bishara J, Weinberger M, Lin AY, Pitlik S. Amphotericin B – not so terrible. Ann Pharmacother. 2001;35(3):308–10.

    Article  CAS  PubMed  Google Scholar 

  90. Googe JH, Walterspiel JN. Arrhythmia caused by amphotericin B in a neonate. Pediatr Infect Dis J. 1988;7(1):73.

    Article  CAS  PubMed  Google Scholar 

  91. DeMonaco HJ, McGovern B. Transient asystole associated with amphotericin B infusion. Drug Intell Clin Pharm. 1983;17(7–8):547–8.

    CAS  PubMed  Google Scholar 

  92. Moyssakis I, Vassilakopoulos TP, Sipsas NV, Perakis A, Petrou A, Kosmas N, et al. Reversible dilated cardiomyopathy associated with amphotericin B treatment. Int J Antimicrob Agents. 2005;25(5):444–7. doi:10.1016/j.ijantimicag.2005.02.015.

    Article  CAS  PubMed  Google Scholar 

  93. Burke D, Lal R, Finkel KW, Samuels J, Foringer JR. Acute amphotericin B overdose. Ann Pharmacother. 2006;40(12):2254–9. doi:10.1345/aph.1H157.

    Article  CAS  PubMed  Google Scholar 

  94. Cleary JD, Hayman J, Sherwood J, Lasala GP, Piazza-Hepp T. Amphotericin B overdose in pediatric patients with associated cardiac arrest. Ann Pharmacother. 1993;27(6):715–9.

    CAS  PubMed  Google Scholar 

  95. Perlman JM, Acarregui M, Gard JW. Fatal overdose of amphotericin B in two preterm infants. Dev Pharmacol Ther. 1991;17(3–4):187–90.

    CAS  PubMed  Google Scholar 

  96. Wang GS, Banerji S, Roussil TK, Heard KJ. Survival after amphotericin B overdose treated with plasmapheresis. Ann Pharmacother. 2013;47(2):e9. doi:10.1345/aph.1R527.

    Article  PubMed  Google Scholar 

  97. Isetta C, Garaffo R, Bastian G, Jourdan J, Baudouy M, Milano G. Life-threatening 5-fluorouracil-like cardiac toxicity after treatment with 5-fluorocytosine. Clin Pharmacol Ther. 2000;67(3):323–5.

    Article  CAS  PubMed  Google Scholar 

  98. Steger F, Hautmann MG, Kolbl O. 5-FU-induced cardiac toxicity – an underestimated problem in radiooncology? Radiat Oncol. 2012;7:212.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  99. Fink M, Zerlauth U, Kaulfersch C, Rab A, Alberer D, Preiss P, et al. A severe case of haemodynamic instability during anidulafungin administration. J Clin Pharm Ther. 2013;38(3):241–2. doi:10.1111/jcpt.12046.

    Article  CAS  PubMed  Google Scholar 

  100. Robbins B, Chang CT, Cramer JA, Garreffa S, Hafkin B, Hunt TL, et al. Safe coadministration of terbinafine and terfenadine: a placebo-controlled crossover study of pharmacokinetic and pharmacodynamic interactions in healthy volunteers. Clin Pharmacol Ther. 1996;59(3):275–83. doi:10.1016/S0009-9236(96)80005-1.

    Article  CAS  PubMed  Google Scholar 

  101. Behr ER, January C, Schulze-Bahr E, Grace AA, Kaab S, Fiszman M, et al. The International Serious Adverse Events Consortium (iSAEC) phenotype standardization project for drug-induced torsades de pointes. Eur Heart J. 2013;34(26):1958–63. The paper describes a consensus effort to standardize the evaluation and reporting of drug-induced TdP events. The recommendations for the required data for case submissions and extended findings should be considered when documenting any case of drug-related TdP.

    Article  PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

DE Nix declares no conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. University of Arizona College of Pharmacy, P.O. Box 210207, Tucson, AZ, 85719, USA

    David E. Nix

Authors
  1. David E. Nix
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David E. Nix.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nix, D.E. Cardiotoxicity Induced by Antifungal Drugs. Curr Fungal Infect Rep 8, 129–138 (2014). https://doi.org/10.1007/s12281-014-0183-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12281-014-0183-0

Keywords

Search

Navigation